Skip to main
DFTX

DFTX Stock Forecast & Price Target

DFTX Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Definium Therapeutics is developing a promising drug pipeline, with a late-stage candidate receiving FDA Breakthrough Therapy Designation for Generalized Anxiety Disorder (GAD). In addition, the company is exploring the potential of DT402 for the treatment of autism spectrum disorder (ASD), which was well-received by industry experts at a recent psychedelics conference. The company has a strong potential for sales and revenue growth with its lead drug DT120, and with the current positive market sentiment towards psychedelics, there is a possibility for upside in its valuation. However, the company remains focused on progressing its drug to market and does not currently have a sustainability plan in place. It may face challenges in securing patent protection for its drugs, but the company could rely on regulatory exclusivity to defend against generics.

Bears say

Definium Therapeutics is facing several potential risks, including a higher than expected net loss in its latest quarter and potential safety concerns with its experimental drug DT120. While the company has received FDA breakthrough designation for DT120 in anxiety and depression, there is a risk that early positive data may not be replicable in larger trials. Furthermore, the company faces challenges in manufacturing and commercializing a controlled substance like LSD. These risks may limit the company's market access and hinder its potential for commercial success.

DFTX has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Definium Therapeutics Inc (DFTX) Forecast

Analysts have given DFTX a Buy based on their latest research and market trends.

According to 8 analysts, DFTX has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Definium Therapeutics Inc (DFTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.